Shares of Supernus (Nasdaq: SUPN ) were down 31.5% in November, although the company is still trading at 50% above its IPO price. The majority of that drop came after the company's recent share offering. The company hopes to commercialize its extended-release epilepsy drugs in 2013. Motley Fool health care analyst David Williamson tells us whether he thinks the lower price and potential of its drugs makes Supernus a buy -- or one to avoid at the moment.
Meanwhile, Supernus competitor Abbott Labs is undergoing a radical transformation. With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.